Envoy Medical, Inc. Form 8-K Summary
Reporting date: October 20, 2023; the report was signed October 24, 2023. The filing reports an auditor change following the September 29, 2023 business combination between Anzu Special Acquisition Corp. I and Envoy Medical Corporation.
Business Context and Reporting Period
Envoy Medical, Inc. is a Delaware corporation whose Class A common stock trades under “COCH” and redeemable warrants trade under “COCHW” on Nasdaq. The company is an emerging growth company. This Form 8-K was filed under Item 4.01, Changes in Registrant’s Certifying Accountant.
Financial Metrics and Liquidity
The filing does not provide current-period revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Grant Thornton LLP was engaged effective October 20, 2023 as the independent registered public accounting firm to audit the consolidated financial statements for the year ending December 31, 2023.
- Grant Thornton had served as the independent auditor of Envoy Medical Corporation before the business combination.
- WithumSmith+Brown, PC was dismissed effective October 20, 2023. Withum had audited Anzu Special Acquisition Corp. I before the business combination.
- Withum’s reports for the years ended December 31, 2022 and 2021 contained going-concern explanatory paragraphs, but were not adverse, disclaimed, qualified, or modified regarding audit scope or accounting principles.
- The company reported no disagreements with Withum regarding accounting principles, financial statement disclosure, or audit scope or procedures.
- The company disclosed previously reported material weaknesses in internal control over financial reporting as the only reportable events identified during the periods described.
Guidance, Risks, and Unusual Items
No financial guidance or operating outlook was provided. The historical going-concern language in Withum’s audit reports and the disclosed material weaknesses are items investors should consider, although the filing does not provide an updated going-concern assessment for Envoy Medical, Inc.
The company stated that it did not consult with Grant Thornton regarding accounting, auditing, or financial reporting matters involving significant advice, disagreements, or reportable events before the engagement.
Investor Verification Items
- Confirm Grant Thornton’s audit scope and the company’s year-end 2023 financial reporting.
- Review the company’s latest periodic filings for the status and remediation of disclosed material weaknesses.
- Assess the impact of the historical going-concern uncertainties reported for Anzu.
- Review Exhibit 16.1 for Withum’s response to the company’s disclosures.
- Verify that the September 29, 2023 business combination and resulting capital structure are reflected consistently in subsequent financial statements.